Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population

Sponsor
Wicab (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04725760
Collaborator
(none)
125
7
1
24
17.9
0.7

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate the effectiveness and safety of the BrainPort® Vision Pro, an electronic oral assistive device, in the performance of daily tasks by French persons who have residual vision limited to light perception or less in both eyes.

Condition or Disease Intervention/Treatment Phase
  • Device: BrainPort Vision Pro
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
125 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population
Actual Study Start Date :
Oct 1, 2020
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single Group Assisgnment

Device: BrainPort Vision Pro
Ten hours of training over 3 to 5 days, followed by autonomous use of the device. It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months.

Outcome Measures

Primary Outcome Measures

  1. Visual Function [Baseline]

    Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision. 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability)

  2. Visual Function [3 months]

    Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability)

  3. Visual Function [6 months]

    Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability)

  4. Visual Function [12 months]

    Ultra Low Vision - Visual Function Questionnaire - 50 (ULV-VFQ-50), Aa validated self-assessment scale to measure functional vision in people with ultra low vision 50 items on a Likert scale, ranging from 1-4, higher scores indicated more difficult (lower visual ability)

Secondary Outcome Measures

  1. Object recognition [Baseline]

    Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded.

  2. Character identification [Baseline]

    High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented.

  3. Orientation and mobility tasks [Baseline]

    This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways.

  4. Object recognition [3 months]

    Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded.

  5. Character identification [3 months]

    High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented.

  6. Orientation and mobility tasks [3 months]

    This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways.

  7. Object recognition [6 months]

    Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded.

  8. Character identification [6 months]

    High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented.

  9. Orientation and mobility tasks [6 months]

    This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways.

  10. Object recognition [12 months]

    Subjects will be asked to reach and grasp one of four objects requested by the examiner, without touching any other object. A total of 10 tests will be conducted. If the test is not answered after two minutes, the test will be considered incorrect. The number of correctly identified objects will be recorded.

  11. Character identification [12 months]

    High contrast letters and numbers will be presented. Subjects will be required to orally identify each letter or number presented. The total number of correct answers will be recorded. Ten individual letters/numbers will be presented.

  12. Orientation and mobility tasks [12 months]

    This task will measure participants' ability to navigate a room and identify distinct objects and features in their environment, such as windows and doorways.

  13. Impact of Vision Impairment-Very Low Vision Quality of Life Scale [Baseline]

    A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life.

  14. Impact of Vision Impairment-Very Low Vision Quality of Life Scale, [3 months]

    A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life.

  15. Impact of Vision Impairment-Very Low Vision Quality of Life Scale, [6 months]

    A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life.

  16. Impact of Vision Impairment-Very Low Vision Quality of Life Scale, [12 months]

    A vision-related quality of life scale for participants with very low vision 28 items on a Likert scale, ranging from 1-3 with higher scores indicating better vision-related quality of life.

  17. Adverse events related to device or study procedures [12 months]

    Safety

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. 8 years of age or older

  2. Diagnosis of profound blindness with residual vision limited to a perception of light or lower in both eyes.

  3. Minimum post 12 months diagnosis of blindness

  4. Previously completed conventional rehabilitation such as orientation and mobility training with a cane or guide dog.

  5. Ability to be read and to understand the documentation and procedures of the study.

  6. Ability to provide feedback on the use of the BrainPort Vision Pro device.

  7. Ability to use basic computer and/or other technologies.

  8. Willing and able to answer all questionnaires, carry out telephone follow-ups, undergo device training and carry out all study procedures, after having passed the orientation phase with the device.

  9. Participant or his legal representative willing and able to sign informed consent.

Exclusion Criteria:
  1. Ongoing oral disorders determined on the basis of the participant's medical history and/or by an examination of the oral cavity by a dental specialist.

  2. History of tongue damage resulting in sensitivity problems or impaired language.

  3. Visible open sores, herpes, abrasions, blisters or rashes on the tongue or numbness of the tongue.

  4. Piercings on the tongue.

  5. Planned or recent oral surgery (in the last 3 months) and/or dental care (excluding oral check-ups or routine scaling).

  6. Known neuropathy of the language or sensory system.

  7. History of seizures or epilepsy.

  8. Pregnant woman, willing to be pregnant or lactating. Women of childbearing age should consent to the use of appropriate contraception to avoid pregnancy during the study period.

  9. Implanted medical devices (e.g., pacemaker, deep brain stimulation device, cochlear implant).

  10. Any hearing impairment that prevents you from hearing the device's announcements.

  11. Cognitive impairment detected on the basis of medical history and/or during a cognitive impairment telephone interview.

  12. Expected or ongoing participation in another clinical trial or any research that may interfere with this study.

  13. Known allergy to nickel, gold or a stainless-steel component.

  14. Any health condition that may interfere with the study's evaluations.

  15. A person unable to assemble the device and/or interpret the device's signals or who refuses to continue to participate in the study after passing the initial training phase with the device.

  16. Person deemed unfit to participate in the study by the lead investigator for any other previously cited reason.

  17. Adults who do not have the ability to provide valid informed consent (under legal protection)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital La Timone Marseille France
2 CHU de Montpellier Montpellier France
3 University Hospital of Nantes Nantes France
4 Institut Aramav Nimes France
5 Fondation hospitalière Sainte-Marie Paris France
6 Necker-Enfants Malades Hospital Paris France
7 Hôpitaux Universitaires de Strasbourg, Reference Center for Rare Disorders in Ophthalmic Genetics Strasbourg France

Sponsors and Collaborators

  • Wicab

Investigators

  • Study Director: Patricia Grant, Ph.D., Wicab, Inc.
  • Principal Investigator: Isabelle Audo, Ph.D., National Hospital for Ophthalmology of the Fifteen-Vingts

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Wicab
ClinicalTrials.gov Identifier:
NCT04725760
Other Study ID Numbers:
  • 2020-WIFR-8313
First Posted:
Jan 27, 2021
Last Update Posted:
Nov 10, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Wicab
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 10, 2021